Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes.
about
Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?Tetracycline-inducible protein expression in pancreatic cancer cells: effects of CapG overexpression.Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment.A dynamic plasma membrane proteome analysis of alcohol-induced liver cirrhosis.shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening.Tetracycline regulated systems in functional oncogenomics.Plasma membrane proteome analysis of the early effect of alcohol on liver: implications for alcoholic liver disease.Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor.Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cellsShort-term starvation is a strategy to unravel the cellular capacity of oxidizing specific exogenous/endogenous substrates in mitochondria.Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates.Stem Cell-Based Toxicity ScreeningAn update on metabolism studies using human hepatocytes in primary culture
P2860
Q27024267-0F323735-F96C-4418-BCA6-941F47CD00A2Q34863173-90D30F59-32E2-411B-8022-247D89DD7836Q35667098-73B1A694-88DE-4A92-A24A-875B732808BDQ36571861-88242B3F-4AB0-4BF8-9A3A-546DF9A59B66Q36579671-D0955B75-C565-4905-8699-0A17C93A59B4Q37121662-03B7B73D-AA20-4ED5-A030-CC5BBB044EAEQ37756278-605192CC-5E0F-42FB-AA74-5FF8203B78E3Q38104340-9E87FD4E-140D-4AC4-A1A9-833079CE0B12Q38504104-5A09C84B-B758-4306-9B21-5C95AA8C71FCQ38743580-0767538C-5F15-43DF-B154-4BEF75404E7FQ38785882-FC1224EE-FA0D-43C0-ABA4-4181F007C35CQ39873984-A3034074-E74F-44E1-BC80-33C9DB25DEDFQ42511783-CFB2C9E9-B72D-4B9A-9631-B40C789BE933Q45356502-BF76E9A8-B107-49DA-9450-25DE3D5C83F6Q55885235-AEB51B8E-D73C-4EE3-8DE4-9B37F0B44D77Q58680978-DDE82F53-0049-44FB-BBFF-5606FC6F5B16
P2860
Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Development of a transactivato ...... I, and chemical defense genes.
@en
type
label
Development of a transactivato ...... I, and chemical defense genes.
@en
prefLabel
Development of a transactivato ...... I, and chemical defense genes.
@en
P2093
P2860
P50
P1476
Development of a transactivato ...... II, and chemical defense genes
@en
P2093
Alec Simpson
Azman Abdullah
B Kevin Park
Brian Foster
Cerys A Lovatt
Chris E P Goldring
Christian Berens
Lesley McLellan
Neil R Kitteringham
Peter Metcalfe
P2860
P304
P356
10.1152/AJPCELL.00133.2005
P577
2005-08-31T00:00:00Z